

tions (5), can be achieved through sequence (23) or regulatory (24) changes in the core genome. Nonetheless, given their prevalence, mobility, and expression under relevant conditions, islands likely play a role in adaptation, but on shorter time scales, or more local spatial scales, in the context of large populations that harbor substantial genomic variability.

Thus, although streamlined for life in the oligotrophic oceans, the genomes of HL *Prochlorococcus* are not static. Cell-to-cell genome variability is concentrated in islands containing genes that are differentially expressed under stresses typical of oceanic environments. Just as pathogenicity islands alter the host specificity and virulence of pathogenic bacteria (3), genomic islands in *Prochlorococcus* may contribute to niche differentiation in the surface oceans. Although other factors, such as small insertions and deletions, substitutions in homologous proteins, and differential regulation are important contributors to diversity, the prevalence of genomic islands and their features argue that these also play an influential role. We postulate that lateral gene transfer in genomic islands is an important mechanism for local specialization in the oceans. If true, genomic islands of natural taxa should contain genes that are ecologically important in a given environment, regardless of the core genome phylogeny.

Testing this hypothesis will not only advance our understanding of microbial diversity in the ocean, but also contribute to a unified understanding of genomic evolutionary mechanisms and their impact on microbial ecology.

#### References and Notes

1. R. A. Welch *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **99**, 17020 (2002).
2. J. R. Thompson *et al.*, *Science* **307**, 1311 (2005).
3. J. Hacker, J. B. Kaper, *Annu. Rev. Microbiol.* **54**, 641 (2000).
4. L. R. Moore, G. Rocoap, S. W. Chisholm, *Nature* **393**, 464 (1998).
5. Z. I. Johnson *et al.*, *Science* **311**, 1737 (2006).
6. E. R. Zinser *et al.*, *Appl. Environ. Microbiol.* **72**, 723 (2006).
7. N. Ahlgren, G. Rocoap, S. W. Chisholm, *Environ. Microbiol.* **8**, 441 (2006).
8. N. J. West, D. J. Scanlan, *Appl. Environ. Microbiol.* **65**, 2585 (1999).
9. N. J. West *et al.*, *Microbiology* **147**, 1731 (2001).
10. G. Rocoap *et al.*, *Nature* **424**, 1042 (2003).
11. K. T. Konstantinidis, J. M. Tiedje, *Proc. Natl. Acad. Sci. U.S.A.* **102**, 2567 (2005).
12. A. Dufresne, L. Garczarek, F. Partensky, *Genome Biol.* **6**, R14 (2005).
13. W. D. Reiter, P. Palm, S. Yeats, *Nucleic Acids Res.* **17**, 1907 (1989).
14. W. W. Hsiao *et al.*, *PLoS Genet.* **1**, e62 (2005).
15. M. B. Sullivan, M. L. Coleman, P. Weigele, F. Rohwer, S. W. Chisholm, *PLoS Biol.* **3**, e144 (2005).
16. D. Lindell *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **101**, 11013 (2004).
17. Q. He, N. Dolganov, O. Bjorkman, A. R. Grossman, *J. Biol. Chem.* **276**, 306 (2001).
18. D. H. Stewart, G. W. Brudvig, *Biochim. Biophys. Acta* **1367**, 63 (1998).

19. A. Wright, M. McConnell, S. Kanegasaki, in *Virus Receptors*, L. L. Randall, L. Philipson, Eds. (Chapman and Hall, New York, 1980), pp. 27–57.
20. J. A. Fuhrman, *Nature* **399**, 541 (1999).
21. J. C. Venter *et al.*, *Science* **304**, 66 (2004).
22. E. F. DeLong *et al.*, *Science* **311**, 496 (2006).
23. G. N. Somero, *Annu. Rev. Physiol.* **57**, 43 (1995).
24. M. M. Riehle, A. F. Bennett, R. E. Lenski, A. D. Long, *Physiol. Genomics* **14**, 47 (2003).
25. Materials and methods are available as supporting material on Science Online.
26. We thank T. Rector, N. Hausman, and R. Steen for Affymetrix microarray processing; M. Polz for helpful discussions; and D. Lindell and A. Tolonen for comments on the manuscript. This work was supported by grants from NSF Biological Oceanography (S.W.C.) and Microbial Observatory (E.F.D.) Programs, the U.S. Department of Energy (DOE) GTL Program (to S.W.C. and G. Church), and the Gordon and Betty Moore Foundation (S.W.C. and E.F.D.). Sequencing support came from the DOE Microbial Genomics Program (E.F.D.) and DOE GTL and Community Sequencing Program (S.W.C.), conducted at the DOE Joint Genome Institute. Sequences are available in GenBank: BX548174 (MED4 genome), CP000111 (MIT9312 genome), and DQ366711 to DQ366746 (environmental genome fragments).

#### Supporting Online Material

www.sciencemag.org/cgi/content/full/311/5768/1768/DC1  
Materials and Methods  
Figs. S1 to S5  
Tables S1 to S3  
References

31 October 2005; accepted 17 February 2006  
10.1126/science.1122050

## Toll-Like Receptor Triggering of a Vitamin D–Mediated Human Antimicrobial Response

Philip T. Liu,<sup>1,2\*</sup> Steffen Stenger,<sup>4\*</sup> Huiying Li,<sup>3</sup> Linda Wenzel,<sup>4</sup> Belinda H. Tan,<sup>1,2</sup> Stephan R. Krutzik,<sup>2</sup> Maria Teresa Ochoa,<sup>2</sup> Jürgen Schaubert,<sup>5</sup> Kent Wu,<sup>1</sup> Christoph Meinken,<sup>4</sup> Diane L. Kamen,<sup>6</sup> Manfred Wagner,<sup>7</sup> Robert Bals,<sup>8</sup> Andreas Steinmeyer,<sup>9</sup> Ulrich Zügel,<sup>10</sup> Richard L. Gallo,<sup>5</sup> David Eisenberg,<sup>3</sup> Martin Hewison,<sup>11</sup> Bruce W. Hollis,<sup>12</sup> John S. Adams,<sup>11</sup> Barry R. Bloom,<sup>13</sup> Robert L. Modlin<sup>1,2†</sup>

In innate immune responses, activation of Toll-like receptors (TLRs) triggers direct antimicrobial activity against intracellular bacteria, which in murine, but not human, monocytes and macrophages is mediated principally by nitric oxide. We report here that TLR activation of human macrophages up-regulated expression of the vitamin D receptor and the vitamin D-1-hydroxylase genes, leading to induction of the antimicrobial peptide cathelicidin and killing of intracellular *Mycobacterium tuberculosis*. We also observed that sera from African-American individuals, known to have increased susceptibility to tuberculosis, had low 25-hydroxyvitamin D and were inefficient in supporting cathelicidin messenger RNA induction. These data support a link between TLRs and vitamin D–mediated innate immunity and suggest that differences in ability of human populations to produce vitamin D may contribute to susceptibility to microbial infection.

The innate immune system provides a rapid host mechanism for defense against microbial pathogens. In *Drosophila*, innate immunity is mediated in part by the Toll family of pattern-recognition receptors, whose activation induces expression of a series of antimicrobial peptides (1). The mammalian TLR homologs, in-

cluding the TLR2 and TLR1 heterodimer (2), similarly recognize a variety of microbial-derived ligands, including bacterial lipopeptides. Activation of TLRs results in a direct antimicrobial response in monocytes and macrophages in vitro. In mice, this activity is mediated principally through generation of nitric oxide (3, 4). How-

ever, we found that TLR2/1-induced antimicrobial activity in human macrophages is not affected by inhibitors of nitric oxide or reactive oxygen intermediates (5), and the mechanism of human microbicidal activity remains unresolved.

In studies of resistance to *M. tuberculosis*, we observed that activation of TLR2/1 reduced the viability of intracellular *M. tuberculosis* in human monocytes and macrophages but not in monocyte-derived dendritic cells (DCs) [Fig. 1A and (5, 6)]. Consequently, we used DNA microarrays to examine gene expression profiles of monocytes and DCs stimulated with a synthetic 19-kD *M. tuberculosis*-derived lipopeptide (TLR2/1L) or treated with medium (6). A two-way ANOVA was applied to the array data to identify genes differentially expressed in the two cell types after TLR2/1L treatment (6). Genes up-regulated in monocytes, but not in DCs, with significant *P* values [*P* < 0.05; the false discovery rate (FDR), which is the expected proportion of false rejections among all rejections, was 0.09] were cross-referenced against a list of genes associated with known antimicrobial function, yielding two candidates: vitamin D receptor (VDR) and S100A12, a calcium-binding pro-inflammatory molecule (7) (Fig. 1B). Although TLR2/1 stimulation of DCs up-regulated specific genes characteristic of activation (Fig. 1B), the selective up-regulation of the VDR gene in monocytes prompted us to examine further selected VDR-related genes. From these analyses,

Cyp27B1, the enzyme that catalyzes the conversion of inactive provitamin D<sub>3</sub> hormone [25-hydroxyvitamin D<sub>3</sub>; 25(OH)D<sub>3</sub>] into the active form [1,25-dihydroxyvitamin D<sub>3</sub>; 1,25(OH)<sub>2</sub>D<sub>3</sub>], was observed to be significantly up-regulated at 12 and 24 hours (Fig. 1C). However, there was no evidence for mRNA up-regulation of other VDR downstream target genes, including cathelicidin antimicrobial peptide (CAMP) (a cathelicidin precursor), β-defensin 4 (DEFB4), and the 1,25(OH)<sub>2</sub>D<sub>3</sub>-regulated VDR-specific Cyp24 hydroxylase gene (Fig. 1C) (8). Quantitative polymerase chain reaction (qPCR) confirmed the microarray data, demonstrating up-regulation of mRNAs for both VDR and Cyp27B1 in monocytes and macrophages, but not DCs (Fig. 1D) (6). However, again no observable up-regulation of cathelicidin, DEFB4, and Cyp24 mRNAs was seen in TLR2/1L-treated monocytes (Fig. 1E). Together, these data suggest that TLR induces up-regulation of the VDR and Cyp27B1 gene expression in monocytes and macrophages, but raise the question of its functional significance.


To determine the functional status of the VDR, 1,25(OH)<sub>2</sub>D<sub>3</sub> was added to primary human monocytes, and downstream target gene induction was assessed. Treatment led to the dose-dependent up-regulation of both cathelicidin and Cyp24 mRNA by qPCR, although the expression of DEFB4 remained unchanged (Fig. 2A). The induction of cathelicidin was also evident by intracellular flow cytometry and was found to be processed to its active peptide form (LL-37) by surface-enhanced laser desorption ionization–time of flight (SELDI-TOF) mass spectrometry (Fig. 2, B and C) (6). In monocytes infected with *Mycobacterium bovis* Bacille Calmette-Guérin-expressing green fluorescent protein (BCG-GFP), cathelicidin was observed to colocalize with the bacteria-containing vacuoles with 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment, but not in untreated samples (Fig. 2D) (6). A direct antimicrobial effect of the cathelicidin peptide on

*M. tuberculosis* could be demonstrated by both [<sup>3</sup>H]uracil uptake and colony-forming unit (CFU) assay (Fig. 2E) (6). Addition of 1,25(OH)<sub>2</sub>D<sub>3</sub> to primary human macrophages infected with virulent *M. tuberculosis* reduced the number of viable bacilli (Fig. 2F), consistent with earlier studies performed with monocytic cell lines (9, 10). Taken together, these data indicate that the VDR is functional in primary human monocytes and that its activation triggers induction of at least one known antimicrobial peptide, cathelicidin, capable of mediating antimicrobial activity.

Because the VDR is functional when exogenous 1,25(OH)<sub>2</sub>D<sub>3</sub> is added, we hypothesized that the TLR2/1 induction of Cyp27B1 and the conversion of 25(OH)D<sub>3</sub> to 1,25(OH)<sub>2</sub>D<sub>3</sub> could represent key aspects of the TLR pathway. Monocytes were activated by TLR2/1L in medium containing fetal calf serum (FCS), in the presence and absence of 25(OH)D<sub>3</sub>. Although addition of either 25(OH)D<sub>3</sub> or TLR2/1L alone had no effect, their simultaneous addition up-

regulated cathelicidin and Cyp24 mRNA (Fig. 3A). In the viability assays, where exogenous 25(OH)D<sub>3</sub> was not required for killing, the experiments were performed in human serum to facilitate uptake of bacteria. Only in the presence of human serum did the TLR2/1 stimulation up-regulate cathelicidin and Cyp24 mRNA without addition of exogenous 25(OH)D<sub>3</sub> (Fig. 3B). We attribute this to the finding that the 25(OH)D<sub>3</sub> levels in human serum were five times those in FCS (Fig. 3C), which suggests that culture of human cells in human serum may be critical for study of innate immune responses in humans (6).

Specific inhibition of Cyp27B1 blocked TLR2/1L activation of cathelicidin mRNA by 80% (Fig. 4A). Addition of a VDR antagonist inhibited induction of cathelicidin mRNA by greater than 80% (Fig. 4B), and the antimicrobial activity was reduced about 70% (Fig. 4C). Taken together, these data demonstrate that activation of TLRs on human monocytes triggers a microbicidal pathway that is dependent



**Fig. 1.** Comparison of gene expression profiles in human primary monocytes and macrophages and DCs. (A) Antimicrobial activity of monocytes, macrophages, and DCs against intracellular *M. tuberculosis*. Infected cells were stimulated with a TLR2/1 ligand, and viable *M. tuberculosis* was assessed by CFU assay. Data shown are representative of 12 individual donors for both cell types. (B) Gene expression profile in TLR2/1L-activated monocytes and DCs. Cells were obtained from four donors, stimulated with TLR2/1L for 12 hours, and their gene expression was profiled by gene microarrays. A two-way ANOVA was applied, and genes induced in monocytes and significantly different ( $P < 0.05$ ) from DCs were cross-referenced against genes with known antimicrobial functions. The profile of genes known to be characteristic of DC function, DC-LAMP maturation marker, the intercellular cell adhesion molecule ICAM1, and CD40 were examined. (C) Time course of Cyp27B1, cathelicidin, DEFB4, and Cyp24 mRNA expression in TLR2/1L-activated monocytes. Cells from four donors were stimulated with either medium (◇) or TLR2/1L (◆) for 0, 3, 6, 12, or 24 hours, and the gene expression was profiled by using microarrays. Regulation of VDR and Cyp27B1 mRNA (D) and cathelicidin, DEFB4, and Cyp24 mRNA (E) in monocytes, macrophages, and DCs. Cells were treated with TLR2/1L at 24 hours, and gene expression was assessed by qPCR (mean fold change  $\pm$  SEM,  $n = 4$ ). \* $P \leq 0.05$ , \*\* $P \leq 0.01$ .

<sup>1</sup>Department of Microbiology, Immunology, and Molecular Genetics; <sup>2</sup>Division of Dermatology, Department of Medicine, David Geffen School of Medicine; <sup>3</sup>Department of Chemistry and Biological Chemistry, Howard Hughes Medical Institute; and Department of Energy Institute of Genomics and Proteomics, University of California at Los Angeles, Los Angeles, CA 90095, USA. <sup>4</sup>Institut für Klinische Mikrobiologie, Immunologie, und Hygiene, Universität Erlangen, D-91054 Erlangen, Germany. <sup>5</sup>Division of Dermatology, University of California at San Diego, and Veterans Affairs San Diego Healthcare Center, San Diego, CA 92161, USA. <sup>6</sup>Department of Medicine, Medical University of South Carolina (MUSC), Charleston, SC 29425, USA. <sup>7</sup>Klinikum Nürnberg, Medizinische Klinik 3, D-90340 Nürnberg, Germany. <sup>8</sup>Pneumologie, Universität Marburg, D-35043 Marburg, Germany. <sup>9</sup>Medical Chemistry, <sup>10</sup>Corporate Research Business Area (CRBA) Dermatology, Schering AG, D-13342 Berlin, Germany. <sup>11</sup>Department of Medicine, Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. <sup>12</sup>Departments of Pediatrics, Biochemistry, and Molecular Biology, MUSC, Charleston, SC 29425, USA. <sup>13</sup>Harvard School of Public Health, Boston, MA 02115, USA.

\*These authors contributed equally to this work.  
 †To whom correspondence should be addressed. E-mail: rmodlin@mednet.ucla.edu



on both the endogenous production and action of 1,25(OH)<sub>2</sub>D<sub>3</sub> through the VDR.

These findings prompted us to address a problem that has long challenged the field, namely, differences in susceptibility of different ethnic populations to the disease. Because of skin melanin content and subsequent diminished ultraviolet (UV) light-dependent cutaneous vita-

min D<sub>3</sub> synthetic capacity, African Americans have significantly decreased serum 25(OH)D<sub>3</sub> levels (11) and are known to have increased susceptibility to *M. tuberculosis* infection (12), as well as more rapid and more severe course of disease (13). We observed that serum levels of 25(OH)D<sub>3</sub> in African Americans were significantly lower than in a Caucasian cohort (Fig. 4D).

Strikingly, when these serum samples were used to support TLR2/1 activation, the induction of cathelicidin mRNA was significantly lower in the presence of serum from African American than the Caucasian individuals [Fig. 4E and (14) (correlation coefficient 25(OH)D<sub>3</sub> versus cathelicidin mRNA = 0.63; *P* < 0.001)]. Finally, supplementation of the African American serum with

**Fig. 2.** Monocyte response to 1,25(OH)<sub>2</sub>D<sub>3</sub> (1,25D3). **(A)** Regulation of VDR downstream genes cathelicidin, Cyp24, and DEFB4 mRNA on stimulation with 1,25(OH)<sub>2</sub>D<sub>3</sub> (mean fold change ± SEM, *n* = 4). **(B)** Detection of cathelicidin in monocytes by intracellular flow cytometry. Monocytes were stimulated with either control (solid line) or 1,25(OH)<sub>2</sub>D<sub>3</sub> (gray shaded area). Isotype control is represented by the dashed line. Data shown are representative of four separate experiments. **(C)** Detection of cathelicidin-derived peptides in monocytes by SELDI-TOF. In three separate experiments, SELDI-TOF analysis of monocyte cell pellets detected a peak around 4.5 kD consistently, as indicated by the arrow, corresponding to the cathelicidin peptide (LL-37). **(D)** Colocalization of mycobacteria and cathelicidin. Monocytes were infected with BCG-GFP (green) then stimulated with 1,25(OH)<sub>2</sub>D<sub>3</sub> and labeled using a monoclonal antibody specific for cathelicidin (red). CD68 is used as a marker for monocytes (blue). Data shown are representative of three separate experiments. **(E)** *M. tuberculosis* viability following incubation with recombinant cathelicidin peptide. Experiments were performed at various concentrations of cathelicidin peptide incubated with bacteria for 3 days. The bacterial viability was measured by both [<sup>3</sup>H]uracil uptake [mean counts per minute ± SEM, *n* = 3] and CFU assay (mean CFU ± SEM, *n* = 3). **(F)** Antimicrobial activity of alveolar macrophages following 1,25(OH)<sub>2</sub>D<sub>3</sub> stimulation. Cells were infected with *M. tuberculosis* and stimulated with 1,25(OH)<sub>2</sub>D<sub>3</sub>. The number of viable *M. tuberculosis* bacteria was assessed by CFU assay. Data shown are representative of four experiments. \*\**P* ≤ 0.01.



**Fig. 3.** Effect of human serum (HS) on vitamin D receptor activation. **(A)** Effects of 25(OH)D<sub>3</sub> (25D3) supplementation to TLR2/1-stimulated monocytes cultured in FCS (mean fold change ± SEM, *n* = 3). **(B)** Effect of FCS and human serum on TLR-induced VDR downstream genes. The ability of monocytes cultured in either FCS or human serum to up-regulate

cathelicidin and Cyp24 mRNA upon TLR2/1L stimulation measured by qPCR (mean fold change ± SEM, *n* = 4). **(C)** 25(OH)D<sub>3</sub> levels in FCS and human serum as measured by radioimmunoassay. FCS data represent the same lot used throughout this study, and human serum is the mean concentration (nM) ± SEM of four individual donors.




25(OH)D<sub>3</sub> to a physiologic range restored TLR induction of cathelicidin mRNA (Fig. 4F).

Although the antimicrobial effects of vitamin D have been previously documented and reduced vitamin D status is known to be associated with susceptibility to *M. tuberculosis* infection, our work describes a potential mechanism by which this might influence the innate immune response. By demonstrating that TLR stimulation of human macrophages induces (i) the enzyme that catalyzes conversion of 25(OH)D<sub>3</sub> to active 1,25(OH)<sub>2</sub>D<sub>3</sub>; (ii) the expression of the vitamin D receptor (VDR); and, (iii) relevant downstream targets of VDR (including cathelicidin), the present results provide an explanation for the action of vitamin D as a key link between TLR activation and antibacterial responses in innate immunity. We do not imply that this is the only antimicrobial

mechanism available to human macrophages. This innate immune pathway is likely complemented by T cell-dependent adaptive immune mechanisms, which include macrophage activation by cytokines and release of granulysin (15).

We believe these findings may explain a number of puzzling problems: the increased 1,25(OH)<sub>2</sub>D<sub>3</sub> levels at the site of disease in a localized form of tuberculosis (16), TLR-induced induction of antimicrobial peptides in epithelial cells (17), and the evolution of divergent antimicrobial pathways in mice (nocturnal animals that use nitric oxide) versus humans (daytime creatures that synthesize vitamin D<sub>3</sub> in the skin on exposure to UV light). These findings also provide new insight into the history of tuberculosis treatment, including the importance of sunlight in the sanatorium movement created by Brehmer

and Trudeau, and the award of the 1903 Nobel Prize for Medicine to Niels Ryberg Finsen for demonstrating that UV light was beneficial to patients with lupus vulgaris, tuberculosis of the skin, consistent with the importance of vitamin D in all forms of tuberculosis. The harmful effects of sunlight are well documented, but there is also epidemiologic evidence that vitamin D sufficiency has a positive association with lower incidences of colorectal and prostate cancers (18). The findings reported here are consistent with the possibility that variation in the ability to synthesize vitamin D, including polymorphisms in the VDR (19), may be a contributing factor to increased tuberculosis susceptibility. Consequently, consideration might be given to clinical trials of inexpensive vitamin D supplementation at appropriate doses to enhance innate immunity to microbial infections and possibly neoplastic disease in African or Asian populations.



**Fig. 4.** Role of the vitamin D pathway in induction of cathelicidin mRNA and antimicrobial activity. Role of VDR (A) and Cyp27B1 (B) in induction of cathelicidin mRNA. Monocytes were cultured in human serum and pretreated with the Cyp27B1 antagonist itraconazole (ITRA) (A) or the VDR antagonist VAZ (VDR-antagonist ZK159222) (B), then induced with TLR2/1L; the cathelicidin mRNA levels were determined by qPCR (mean fold change ± SEM, n = 4). (C) The role of the VDR in TLR2/1L-induced antimicrobial activity. Alveolar macrophages were infected with *M. tuberculosis* and stimulated with medium, TLR2/1L, or TLR2/1L with VAZ. Viable bacteria were quantified by CFU assay after 4 days of growth. Data shown are representative of eight experiments. (D) Serum concentration (nM) of 25(OH)D<sub>3</sub> in African American and Caucasian donors as measured by radioimmunoassay. The mean of the values is represented by the line. (E) Effect of serum from African Americans or Caucasians on TLR2/1L-induced cathelicidin mRNA levels. Monocytes were cultured in either African American or Caucasian serum, activated with TLR2/1L, then cathelicidin mRNA levels were determined by qPCR. Points are fold change of each individual donor tested, with the mean value indicated by the line. (F) Effect of supplementation of African American sera with 25(OH)D<sub>3</sub> on TLR2/1L-induced cathelicidin mRNA levels. Monocytes were cultured in African American sera without supplementation or with exogenous 25(OH)D<sub>3</sub> at physiologic concentrations ranging from 1 to 100 nM to optimize the signal-to-noise ratio due to monocyte variability, then stimulated with the TLR2/1L. Cathelicidin levels were determined by qPCR and averaged (mean fold change ± SEM, n = 3). \*P ≤ 0.05, \*\*P ≤ 0.01.

**References and Notes**

1. S. Tauszig, E. Jouanguy, J. A. Hoffmann, J. L. Imler, *Proc. Natl. Acad. Sci. U.S.A.* **97**, 10520 (2000).
2. R. L. Modlin, G. Cheng, *Nat. Med.* **10**, 1173 (2004).
3. J. Chan, Y. Xing, R. S. Magliozzo, B. R. Bloom, *J. Exp. Med.* **175**, 1111 (1992).
4. J. D. MacMicking *et al.*, *Cell* **81**, 641 (1995).
5. S. Thoma-Uszynski *et al.*, *Science* **291**, 1544 (2001).
6. Materials and methods are available as supporting material on Science Online.
7. J. Roth, T. Vogl, C. Sorg, C. Sunderkotter, *Trends Immunol.* **24**, 155 (2003).
8. T. T. Wang *et al.*, *J. Immunol.* **173**, 2909 (2004).
9. K. A. Rockett *et al.*, *Infect. Immun.* **66**, 5314 (1998).
10. L. M. Sly, M. Lopez, W. M. Nauseef, N. E. Reiner, *J. Biol. Chem.* **276**, 35482 (2001).
11. L. Y. Matsuoka, J. Wortsman, J. G. Haddad, P. Kolm, B. W. Hollis, *Arch. Dermatol.* **127**, 536 (1991).
12. W. W. Stead, J. W. Senner, W. T. Reddick, J. P. Lofgren, *N. Engl. J. Med.* **322**, 422 (1990).
13. A. R. Rich, *The Pathogenesis of Tuberculosis* (Charles C Thomas, Springfield, IL, 1944).
14. All volunteers in the study were categorized by self-identification or visual determination as African Americans or Caucasians (non-Hispanic, White). There were 19 African Americans and 14 Caucasians studied in Fig. 4, D and E. Although the studies were performed using samples from African Americans, we believe that the implications are likely to be relevant for all individuals of African descent and possibly of Asian descent. Future studies will be directed towards comparing responses according to measured skin pigmentation.
15. S. Stenger *et al.*, *Science* **282**, 121 (1998).
16. P. F. Barnes, R. L. Modlin, D. D. Bikle, J. S. Adams, *J. Clin. Invest.* **83**, 1527 (1989).
17. C. J. Hertz *et al.*, *J. Immunol.* **171**, 6820 (2003).
18. E. Giovannucci, *Cancer Causes Control* **16**, 83 (2005).
19. L. Bornman *et al.*, *J. Infect. Dis.* **190**, 1631 (2004).
20. We would like to thank G. Cheng at UCLA for his helpful discussion and O. Sorensen for the cathelicidin antibody. This work was supported by NIH grants AI47868, AI22553, HD043921, AR50626, AI48176, AI052453, AR45676, and RR00425; and also by the Deutsche Forschungsgemeinschaft (SFB 643 and GRK 592); Deutsche Akademie der Naturforscher Leopoldina; and U.S. Department of Veterans Affairs Merit Award.

**Supporting Online Material**

www.sciencemag.org/cgi/content/full/1123933/DC1  
Materials and Methods  
References

16 December 2005; accepted 8 February 2006  
Published online 23 February 2006;  
10.1126/science.1123933  
Include this information when citing this paper.

Downloaded from http://science.sciencemag.org/ on December 11, 2020

## Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response

Philip T. Liu, Steffen Stenger, Huiying Li, Linda Wenzel, Belinda H. Tan, Stephan R. Krutzik, Maria Teresa Ochoa, Jürgen Schaubert, Kent Wu, Christoph Meinken, Diane L. Kamen, Manfred Wagner, Robert Bals, Andreas Steinmeyer, Ulrich Zügel, Richard L. Gallo, David Eisenberg, Martin Hewison, Bruce W. Hollis, John S. Adams, Barry R. Bloom and Robert L. Modlin

*Science* **311** (5768), 1770-1773.

DOI: 10.1126/science.1123933 originally published online February 23, 2006

### ARTICLE TOOLS

<http://science.sciencemag.org/content/311/5768/1770>

### SUPPLEMENTARY MATERIALS

<http://science.sciencemag.org/content/suppl/2006/02/22/1123933.DC1>

### RELATED CONTENT

<http://stke.sciencemag.org/content><http://stke.sciencemag.org/cgi/content/abstract/sigtrans;2006/328/tw110>  
<http://stke.sciencemag.org/content/sigtrans/2006/328/tw110.abstract>

### REFERENCES

This article cites 16 articles, 8 of which you can access for free  
<http://science.sciencemag.org/content/311/5768/1770#BIBL>

### PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

---

*Science* (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science* is a registered trademark of AAAS.

American Association for the Advancement of Science